In this short article, the author states that there were

New Post Public Reply Private Reply Replies (1) Message Board
Buddyboy20 chazzledazzle #141533
659
In this short article, the author states that there were current studies, in progress at UCLA, that were using Maraviroc to see if it would improve cognition. I haven't seen anything showing results yet. However, there should be something out soon. There are a lot of peer reviewed papers that show CCR5 as a prime therapeutic target in Alzheimer's Disease.


MIT Technology Review
SUBSCRIBE

BLOCKCHAIN
China’s CRISPR twins might have had their brains inadvertently enhanced
New research suggests that a controversial gene-editing experiment to make children resistant to HIV may also have enhanced their ability to learn and form memories.
By Antonio Regaladoarchive page
February 21, 2019

JOHN UELAND
The brains of two genetically edited girls born in China last year may have been changed in ways that enhance cognition and memory, scientists say.

The twins, called Lulu and Nana, reportedly had their genes modified before birth by a Chinese scientific team using the new editing tool CRISPR. The goal was to make the girls immune to infection by HIV, the virus that causes AIDS.

Advertisement

Now, new research shows that the same alteration introduced into the girls’ DNA, deletion of a gene called CCR5, not only makes mice smarter but also improves human brain recovery after stroke, and could be linked to greater success in school.

“The answer is likely yes, it did affect their brains,” says Alcino J. Silva, a neurobiologist at the University of California, Los Angeles, whose lab uncovered a major new role for the CCR5 gene in memory and the brain’s ability to form new connections.

“The simplest interpretation is that those mutations will probably have an impact on cognitive function in the twins,” says Silva. He says the exact effect on the girls’ cognition is impossible to predict, and “that is why it should not be done.”

Photo of Dr. Jiankui He
He Jiankui poses for the cameras of the Associated Press in the days before his gene-editing experiments became known.
Mark Schiefelbein | AP
The Chinese team, led by He Jiankui of the Southern University of Science and Technology in Shenzhen, claimed it used CRISPR to delete CCR5 from human embryos, some of which were later used to create pregnancies. HIV requires the CCR5 gene to enter human blood cells.


The experiment has been widely condemned as irresponsible, and He is under investigation in China. News of the first gene-edited babies also inflamed speculation about whether CRISPR technology could one day be used to create super-intelligent humans, perhaps as part of a biotechnology race between the US and China.

There is no evidence that He actually set out to modify the twins’ intelligence. MIT Technology Review contacted scientists studying the effects of CCR5 on cognition, and they say the Chinese scientist never reached out to them, as he did to others from whom he hoped to get scientific advice or support.

“As far as I know, we never heard from him,” says Miou Zhou, a professor at the Western University of Health Sciences in California.

Although He never consulted the brain researchers, the Chinese scientist was certainly aware of the link between CCR5 and cognition. It was first shown in 2016 by Zhou and Silva, who found that removing the gene from mice significantly improved their memory. The team had looked at more than 140 different genetic alterations to find which made mice smarter.

Advertisement

Silva says because of his research, he sometimes interacts with figures in Silicon Valley and elsewhere who have, in his opinion, an unhealthy interest in designer babies with better brains. That’s why, when the birth of the twins became public on November 25, Silva says he immediately wondered if it had been an attempt at this kind of alteration. “I suddenly realized—Oh, holy shit, they are really serious about this bullshit,” says Silva. “My reaction was visceral repulsion and sadness.”

During a summit of gene editing scientists that occurred two days later in Hong Kong, He acknowledged he had known all along about the potential brain effects from the UCLA research. “I saw that paper, it needs more independent verification,” He replied when asked about it during a Q&A session (see video here). He added: “I am against using genome editing for enhancement.”

Whatever He’s true aims, evidence continues to build that CCR5 plays a major role in the brain. Today, for example, Silva and a large team from the US and Israel say they have new proof that CCR5 acts as a suppressor of memories and synaptic connections.

According to their new report, appearing in the journal Cell, people who naturally lack CCR5 recover more quickly from strokes. What’s more, people missing at least one copy of the gene seem to go further in school, suggesting a possible role in everyday intelligence.


“We are the first to report a function of CCR5 in the human brain, and the first to report a higher level of education,” says UCLA biologist S. Thomas Carmichael, who led the new study. He calls the link to educational success “tantalizing” but says it needs further study.

The discoveries about CCR5 are already being followed up in drug trials on both stroke patients and people with HIV, who sometimes suffer memory problems. In those studies, one of which is under way at UCLA, people are being given an anti-HIV drug, Maraviroc, which chemically blocks CCR5, to see if it improves their cognition.

Silva says there is a big difference between trying to correct deficits in such patients and trying to create enhancement. “Cognitive problems are one of the biggest unmet needs in medicine. We need drugs, but it’s another thing to take normal people and muck with the DNA or chemistry to improve them,” he says. “We simply don’t know enough to do it. Nature has struck a very fine balance.”

Just because we shouldn’t alter normal intelligence doesn’t mean we can’t. Silva says the genetic manipulations used to make “smart mice” show not only that it is possible, but that changing CCR5 has particularly big effects.

“Could it be conceivable that at one point in the future we could increase the average IQ of the population? I would not be a scientist if I said no. The work in mice demonstrates the answer may be yes,” he says. “But mice are not people. We simply don’t know what the consequences will be in mucking around. We are not ready for it yet.”

by Antonio Regalado
linkedinlink opens in a new window
twitterlink opens in a new window
facebooklink opens in a new window
emaillink opens in a new window

KEEP READING
MOST POPULAR
This new data poisoning tool lets artists fight back against generative AI
The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models.

By Melissa Heikkiläarchive page
Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist
An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.

By Will Douglas Heavenarchive page
Data analytics reveal real business value
Sophisticated analytics tools mine insights from data, optimizing operational processes across the enterprise.

By MIT Technology Review Insightsarchive page
Driving companywide efficiencies with AI
Advanced AI and ML capabilities revolutionize how administrative and operations tasks are done.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Dorman Products: Anticipating Positive Earnings Ahead

Updated Category News Views 264

Optimistic Earnings Outlook for Dorman Products Dorman Products (NASDAQ: DORM) is gearing up to announce its quarterly earnings report soon, generating buzz among investors. The anticipated release date is approaching, and many are keen to see how the company performs. Expectations Surrounding EPS Analysts have set expectations high, forecasting an earnings per share...

Continue Reading
Fission Uranium Corp. Publishes Results from Special Meeting

Updated Category News Views 53

Fission Uranium Corp. Shares Results from Special Meeting Fission Uranium Corp. (TSX: FCU, OTCQX: FCUUF) recently conducted an important meeting with its securityholders. During this special meeting, the company revealed the results of key votes that will shape its future direction and partnership strategies. Shareholders Express Strong Support for Key Resolutions At the...

Continue Reading
Prevounce Health Enhances Integration with Elation Health's EHR

Updated Category News Views 173

Prevounce Health Partners with Elation Health for Enhanced Care The integration between the Prevounce remote care management platform and the Elation electronic health record (EHR) system marks a significant advancement in healthcare technology. This partnership aims to streamline healthcare processes and enhance patient care through technological synergy. Understanding...

Continue Reading
Exploring the Expanding Landscape of Social Media Listening

Updated Category News Views 196

Growing Demand for Social Media Listening The social media listening market is experiencing remarkable growth, expected to surge from USD 8.36 billion in 2023 to USD 27.63 billion by the year 2032. This projection represents a compound annual growth rate (CAGR) of approximately 14.27% during the forecast period. The increasing need for real-time insights into consumer...

Continue Reading
Orthopedic Braces Market Set to Surge to $5.5 Billion by 2030

Updated Category News Views 123

Overview of the Orthopedic Braces and Supports Market The global orthopedic braces and supports market is currently experiencing significant growth, with a valuation of approximately US$3.8 billion in 2024. This market is expected to reach US$5.5 billion by 2030, showcasing a compound annual growth rate (CAGR) of 6.5% across this period. One of the primary factors...

Continue Reading